Next Generation Immunotherapies Market Revenue Anticipated To Reach $262.81 Billion By 2030 With 11.8% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Market Size Is Forecasted For The Next Generation Immunotherapies Market By 2030 Based On Its 2026 Value?
The next generation immunotherapies market size has experienced rapid expansion in recent years. This market is projected to expand from $150.12 billion in 2025 to reach $168.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. Historically, this growth can be linked to factors such as rising global cancer prevalence, the early success of immune checkpoint inhibitors, increased oncology r&d investments, regulatory approvals of monoclonal antibodies, and growing awareness of immuno-oncology therapies.
The market for next generation immunotherapies is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a value of $262.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This projected growth during the forecast period stems from several factors, including breakthroughs in next-generation antibody engineering, the expansion of applications beyond cancer treatment, the increasing approval of ADC-based therapies, an increase in biomarker-guided treatment choices, and a growing need for therapies that offer lasting and sustained effects. Key trends anticipated for this period encompass the broadening of combination immunotherapy approaches, an increase in personalized cancer vaccines, a growing uptake of bispecific antibodies, a heightened emphasis on mitigating immune-related side effects, and more rapid clinical trial progress for solid tumors.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What Market Drivers Are Helping Shape The Next Generation Immunotherapies Market Expansion?
The growing occurrence of cancer is projected to drive the expansion of the next-generation immunotherapies market. Cancer involves a collection of illnesses marked by the uncontrolled multiplication and dispersion of irregular cells within the body. The widespread presence of cancer stems from factors such as an aging demographic, shifts in lifestyle, environmental exposures, and enhanced diagnostic techniques. Next-generation immunotherapies deliver advanced, targeted treatments designed to strengthen the body’s immune defense against cancer, providing improved efficacy, lasting effects, and tailored approaches. For instance, in July 2024, projections from Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to climb for most types between 2023-2025 and 2038-2040, with increases varying from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are predicted to decrease, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.
Which Segment Divisions Form The Structure Of The Next Generation Immunotherapies Market?
The next generation immunotherapies market covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies
2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
Which Trends Are Influencing The Direction Of The Next Generation Immunotherapies Market?
Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, such as artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These advanced systems utilize artificial intelligence to integrate and analyze various biological data types, including genomic, proteomic, imaging, and clinical information, thereby offering more accurate and individualized cancer detection and diagnosis. For example, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, introduced OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. This platform combines different data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. By using a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights that enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform allows for personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible through OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.
Which Companies Form The Competitive Landscape Of The Next Generation Immunotherapies Market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Access The Complete Next Generation Immunotherapies Market Report:
Which Geographic Region Represents The Largest Next Generation Immunotherapies Market Share?
North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Next Generation Immunotherapies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp
Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company
Next Generation Gynecological Cancer Diagnostics Global Market Report 2026
Breast Cancer Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Oncology Companion Diagnostics Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
